Can a natural spray beat dust mite allergies? new study aims to find out
NCT ID NCT07196527
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a natural nasal spray (Puressentiel Allergy Protection) can reduce symptoms of dust mite allergies. Twenty adults with dust mite allergic rhinitis will receive either the spray or a saline placebo before a nasal allergen challenge. Researchers will measure symptom scores and nasal airflow to see if the spray offers relief.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Puressentiel Allergy Protection Nasal Spray (SNPA)
- What this could lead to
- If it works, this could offer a natural, drug-free option to ease allergy symptoms like sneezing and congestion.
- What could go wrong
- This is a very small, early study with only 20 people. It may not show a clear benefit over plain saline spray.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 20 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Nov 2025
An estimate. Start dates often move.
- Expected to finish
-
Feb 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria:General inclusion criteria: * The patient must have given their express consent to participate in the study. * The patient must be affiliated with or a beneficiary of a health insurance plan. * The patient is at least 18 years of age. Inclusion criteria for the target population: * Patients who have already consulted the allergy department at Montpellier University Hospital. * Patients suffering from perennial rhinitis (or rhino-conjunctivitis) caused by dust mites, diagnosed more than one year ago. * In the case of asthmatic patients, asthma must be under control. * Patients who have been able to stop all treatment with antihistamines or nasal corticosteroids for one week prior to the start of the study (7 days and 1 month, respectively). * Patients covered by social security. Exclusion Criteria:5.4 Exclusion Criteria General exclusion criteria: * The patient is in a period of exclusion determined by a previous study. * The patient is under judicial protection, guardianship, or curatorship. * The patient is a minor. * The patient is not fluent in French. Exclusion criteria regarding interfering diseases or conditions: * The patient is pregnant and/or breastfeeding. * Patient sensitized to a perennial allergen in addition to dust mites. * Patient sensitized to a seasonal allergen, during the allergen's peak pollen season. * Patient who has had a viral infection within 4 weeks prior to the provocation test. * Patient treated or undergoing treatment with allergen immunotherapy. * Patient treated with antihistamines (7-day washout period) or nasal corticosteroids (1-month washout period). * Patients with severe uncontrolled asthma.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Allergic disorder of respiratory system are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.